Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:
-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:8/3/2015)... Silver Spring, MD (PRWEB) , ... August 03, 2015 , ... ... announce the addition of a new associate podiatrist, creating the largest medical practice in ... in foot and ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical Association show ... in their lives. Often time, low back and sciatic pain can happen as a ... managed clinically with powerful pain medication or spinal surgery. Dynamic Health Care in ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... the supportive muscles and connective tissues of a woman’s pelvic organs (uterus, ... damage include straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... ... medical students are in “a trending profession” that comprises a growing percentage of ... needed the most. , That was one part of the message delivered by ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Tina Wilcoxson, owner ... , Wilcoxson was given that honor by the National Retail Federation, the largest retail ... Wilcoxson was one of three Maine business owners to be named as such. According ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Local Retail Advocate Wins National Recognition 2
... 30 (HealthDay News) -- Genes affect hereditary coronary heart disease ... study. While it,s long been known that hereditary factors ... due to genes or unhealthy lifestyle in the family, the ... the investigators examined the health records of 80,214 adopted men ...
... It,s not how old but how frail patients are that can ... fact, young patients in poor health may have worse outcomes than ... the University of Michigan Comprehensive Cancer Center finds that patients with ... spread to distant parts of the body. These findings ...
... found that climate change may lead to more asthma-related health ... the next decade. The data, published in the current ... changing levels of ozone could lead to a 7.3 percent ... The research team, led by Perry Sheffield, ...
... 2011Despite recent concerns that changes in atmospheric pressure during ... via pump devices, the current evidence is limited and ... are available, according to an insightful editorial in ... by Mary Ann Liebert, Inc. The editorial is available ...
... by extroverted college students and their less socially inclined peers ... on partying and drinking to be happy and more on ... positive thinking. "You don,t have to go out ... they need to do, particularly when they,re new to campus," ...
... HealthDay Reporter , TUESDAY, Aug. 30 (HealthDay News) -- Swedish ... seems to be a harbinger of an increased risk of ... strongly tied to the inflammatory processes that are central to ... of the new study, published online Aug. 30 in the ...
Cached Medicine News:Health News:Patients' underlying health linked to worse outcomes for melanoma, U-M study finds 2Health News: Happiness: All in who you know, goals 2Health News:Blood Protein Might Signal Death Risk in Elderly 2
... FSH EIA Test is based ... solid phase enzyme-linked immunosorbent assay. ... monoclonal anti-FSH for solid phase ... anti-alpha FSH in the antibody-enzyme ...
Lyophilized, tri-level assayed human serum-based control, Low, intermediate and high levels, Lot-specific target values provided, Suitable for use with RIA, EIA and chemiluminescent,methodo...
... Hormone (FSH) is intimately involved in the ... of the gonadal tissues, which synthesize and ... The levels of circulating FSH is controlled ... feedback relationship. The FSH Quantitative Test ...
Complete product line for typing all classical HLA loci including A, B, C DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB1, DPA1, and DPB1....
Medicine Products: